Biomarker analysis reveals tumor-intrinsic and tumor microenvironment factors affecting treatment outcomes in large B cell lymphoma patients receiving glofitamab.
Key Points
Tumor-intrinsic characteristics influence initial responses in advancing treatment outcomes.
Key observation of DNA repair pathways showing correlation with resistance and treatment efficacy.
Assessments of differential gene expression suggest multivariate analysis is crucial for understanding patient responses.
The interplay between tumor microenvironment features and treatment outcomes highlights their importance in therapeutic strategies.